# Paramount Biosciences

Paramount Biosciences is a Private Equity based in New York, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Assets under management:** Undisclosed
- **Website:** paramountbiosciences.com
- **LinkedIn:** https://www.linkedin.com/company/paramount-biosciences

## Regulatory record

- **Reports private funds:** No

## About

Paramount Biosciences is a private equity firm based in New York, US. It focuses on a Venture Capital investment approach.

## Sectors

- Healthcare Services
- Digital Health

## Questions

### What is Paramount Biosciences' core investment focus?

Paramount Biosciences invests exclusively in early-stage biotechnology and pharmaceutical companies developing novel human therapeutics. The firm concentrates on preclinical and Phase I/II assets, prioritizing scientific risk evaluation over commercial-stage deal-making. This single-sector mandate distinguishes it from healthcare generalists that also allocate to services, devices, or health IT.

### Who leads investment decisions at Paramount Biosciences?

Paramount's investment decisions are led by managing partners with significant pharmaceutical industry and academic research backgrounds. The team includes principals holding MD or PhD credentials who conduct primary scientific due diligence rather than relying solely on external advisors. Specific named principals have not been widely disclosed in public materials.

### Which therapeutic areas does Paramount prioritize?

Paramount has historically maintained a footprint in oncology, rare genetic diseases, and central nervous system disorders. The firm evaluates platform technologies and single-asset opportunities where biological mechanisms are well-validated but commercial pathways remain undefined. Public disclosures do not specify a comprehensive exclusion list by therapeutic area.

### How is Paramount Biosciences different from a typical healthcare private equity fund?

Paramount deliberately avoids healthcare services, medical devices, diagnostics, and revenue-stage pharmaceutical companies. By restricting its mandate to preclinical and early-clinical therapeutic R&D, the firm takes on concentrated binary risk — a structural choice that sets it apart from multi-asset healthcare platforms common in the New York market.

## Related profiles

- [Parallel Private Equity](https://altss.com/profile/parallel-private-equity)
- [Paris-Saclay Seed Fund](https://altss.com/profile/paris-saclay-seed-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/paramount-biosciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology